Literature DB >> 8302686

Comparison of the pharmacokinetic and pharmacodynamic activity of piperacillin and mezlocillin.

M C Sullivan1, C H Nightingale, R Quintiliani, K Sweeney.   

Abstract

STUDY
OBJECTIVE: To compare serum bactericidal activity over time and pharmacokinetics resulting from single doses of piperacillin (PIP) and a single dose of mezlocillin (MEZ).
DESIGN: Open-label, randomized, three-way crossover study.
SETTING: Hartford Hospital Clinical Research Center. PATIENTS: Nine healthy volunteers.
INTERVENTIONS: Subjects received single doses of PIP 3 and 4 g/70 kg, and a single dose of MEZ 5 g/70 kg.
MEASUREMENTS AND MAIN RESULTS: Test organisms were two clinical isolates of Pseudomonas aeruginosa. Pharmacodynamic analysis revealed that PIP 4 g had 2- to 3-fold higher peak serum bactericidal activity at the end of infusion and 4- to 5-fold higher activity at 0.5 hour than did MEZ 5 g, and also provided approximately 1 hour additional activity over MEZ 5 g. Pharmacokinetic analysis revealed that serum concentrations resulting from PIP 4 g remained above the minimum inhibitory concentration of our test strains almost twice as long as MEZ 5 g.
CONCLUSION: Since mezlocillin 5 g every 8 hours is currently proving to be effective at many institutions, and since piperacillin 4 g demonstrates superior pharmacokinetic and pharmacodynamic activity, we believe that piperacillin 4 g every 8 hours could be used instead, with resulting cost savings.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8302686

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

1.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

2.  Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.

Authors:  N Patel; M H Scheetz; G L Drusano; T P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

3.  Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses.

Authors:  B Auclair; M P Ducharme
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.